NeurologyLive®

@neurology_live

Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible.

United States
neurologylive.com
Vrijeme pridruživanja: srpanj 2018.
1.365 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @neurology_live

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @neurology_live

  1. Prikvačeni tweet
    29. sij

    Join NeurologyLive and the community on Monday, Feb. 3rd at 8PM EST for a tweet chat on in celebration of . Stay tuned for more details on how to participate

    3 proslijeđena tweeta 7 korisnika označava da im se sviđa
    Poništi
  2. prije 19 minuta

    had a sensitivity of 97.4% and specificity of 78.9%, with an added value in the detection of treatment-responsive chronic inflammatory neuropathy of 21.1%.

    Poništi
  3. prije 47 minuta

    “We are now working with US trial sites to initiate this open-label clinical trial, which does not include a placebo-controlled arm. In the US, we expect the first patients to be re-dosed starting in March of this year.”

    1 korisnik označava da mu se sviđa
    Poništi
  4. prije 1 sat

    FDA has approved an autoinjector for the delivery of , an anti-calcitonin gene-related peptide approved for the prevention of in adults.

    Poništi
  5. prije 2 sata

    Experts discuss the differences between botulinum toxins A and B and present their preferences in using these in their practice. Watch "Management Of Sialorrhea In Parkinsons Disease":

    1 korisnik označava da mu se sviđa
    Poništi
  6. prije 2 sata

    The lead author of a recent publication from the Memory and Aging Project discussed the data and what impact flavonol intake might have on the risk of developing disease dementia. Read more from Thomas M. Holland, MD 🧠:

    Poništi
  7. prije 3 sata

    Richard Trosch, MD, discusses the management of with surgical intervention and the adverse effects resulting from oral therapies.

    1 proslijeđeni tweet
    Poništi
  8. prije 3 sata

    “Obtaining an ICD-10 code for CDD is a big milestone for our field and one more step towards having approved therapies and ensuring patient access to these treatments." - Ana Mingorance PhD, LouLou Foundation.

    2 korisnika označavaju da im se sviđa
    Poništi
  9. prije 4 sata

    has been expanded for the treatment of refractory complex partial seizures in patients 2-10 years old.

    Poništi
  10. prije 4 sata

    (Reyvow), an oral medication approved for the acute treatment of with or without aura, is now available for prescription. 🧠 Details on the marketed drug :

    Poništi
  11. prije 5 sati

    NeurologyLive sat down with for a Q&A on the 2019 American College of Emergency Physicians guidelines on acute nontraumatic in the emergency department.

    1 korisnik označava da mu se sviđa
    Poništi
  12. prije 5 sati

    The has approved the investigational new drug application for AV-101 for the treatment of in patients with Parkinson disease who are treated with levodopa. Details:

    2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  13. prije 6 sati

    The has cleared the use of QyScore software in the analysis of brain MRI markers in neurodegenerative diseases such as disease, , and . Read more:

    1 korisnik označava da mu se sviđa
    Poništi
  14. prije 6 sati

    Boys with nonsense mutation Duchenne muscular dystrophy who received (; PTC Therapeutics) and standard of care preserved the ability to walk for years longer.

    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
    Poništi
  15. prije 7 sati

    The has approved an expanded indication for (Belsomra; Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease.

    1 korisnik označava da mu se sviđa
    Poništi
  16. prije 14 sati

    Subgroups and treatment-related changes can be identified with comparative cerebrospinal fluid proteomic analysis in adult patients with spinal muscular atrophy .

    2 korisnika označavaju da im se sviđa
    Poništi
  17. prije 14 sati

    ICYMI: The has approved the investigational new drug application for the HEALEY ALS platform trial. This is the first trial to test the effects of 3 different drugs:

    1 proslijeđeni tweet
    Poništi
  18. prije 15 sati

    New study data showed nerve ultrasound had a sensitivity of 97.4% and specificity of 78.9%, with an added value in the detection of treatment-responsive chronic inflammatory neuropathy of 21.1%.

    1 korisnik označava da mu se sviđa
    Poništi
  19. prije 15 sati

    In episode 6 of our Peers and Perspectives series, experts discuss mechanisms of action and types of botulinum toxic injectables to treat .

    Poništi
  20. prije 16 sati

    Aducanumab, Alzheimer disease treatment from will be re-administered to patients who were previously enrolled in aducanumab trials as they prepare to submit for FDA approval. Details on this trial:

    1 reply 2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
    Poništi
  21. prije 16 sati

    Follow NeurologyLive on LinkedIn and stay up to date with the latest news:

    Poništi

@neurology_live još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·